Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai) (ColHai)
Registro Español de Enfermedades Hepáticas Colestásicas y Autoinmunes (ColHai)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Asociación Española para el Estudio del Hígado Asociación Espa
- Phone Number: 0034915551119
- Email: registrocolhay@gmail.com
Study Locations
-
-
-
Barcelona, Spain
- Recruiting
- Hospital Clinic
-
Contact:
- Maria Carlota Londoño Londoño
- Email: mlONDONO@clinic.cat
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with a confirmed diagnosis for PBC, HAI, PSC, genetic cholestatic disease
Exclusion Criteria:
- Refusal to sign the informed consent for the study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence and characteristics of autoimmune and cholestatic liver disease in Spain
Time Frame: 2025
|
Evaluation of clinical characteristics of autoimmune and cholestatic liver diseases
|
2025
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Development of liver-related events in autoimmune ahd cholestatic liver diseases
Time Frame: 2025
|
2025
|
|
Treatment of autoimmune and cholestatic liver diseases in Spain
Time Frame: 2016-2030
|
2016-2030
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Maria Carlota Londoño Londoño, Asociación Española para el Estudio del Hígado
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
- Registry
- Genetic disease
- Primary Biliary Cholangitis (PBC)
- Alagille syndrome
- Cholestatic Genetic Diseases
- Primary Sclerosing Cholangitis (PSC)
- Hepatitis Autoimmune Disease
- PFIC tipo 1
- PFIC tipo 2
- PFIC tipo 3
- PFIC tipo 4
- BRIC tipo 1
- BRIC tipo 2
- Rotor syndrome
- Dubin Johnson syndrome
- cholestatic diseases
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Digestive System Diseases
- Biliary Tract Diseases
- Liver Diseases
- Bile Duct Diseases
- Fibrosis
- Cholestasis, Intrahepatic
- Cholestasis
- Liver Cirrhosis
- Hepatitis
- Genetic Diseases, Inborn
- Autoimmune Diseases
- Cholangitis
- Cholangitis, Sclerosing
- Liver Cirrhosis, Biliary
Other Study ID Numbers
Other Study ID Numbers
- HCB/2016/0565
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.